TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

Recent studies have suggested that activation of the EGFR pathway leads to malignant transformation only if the p53 protein is inactivated. Therefore, we evaluated the impact of TP53 mutations on cetuximab-based chemotherapy (CT) sensitivity in combination with KRAS mutations that have been associat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Oden-Gangloff, A, Di Fiore, F, Bibeau, F, Lamy, A, Bougeard, G, Charbonnier, F, Blanchard, F, Tougeron, D, Ychou, M, Boissière, F, Le Pessot, F, Sabourin, J-C, Tuech, J-J, Michel, P, Frebourg, T
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2009
Assuntos:
Molecular Diagnostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2676556/
https://ncbi.nlm.nih.gov/pubmed/19367287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados